rs1555903969
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PVS1PM2PP5
The NM_000026.4(ADSL):c.153+1G>T variant causes a splice donor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000689 in 1,450,776 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000026.4 splice_donor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ADSL | ENST00000623063.3 | c.153+1G>T | splice_donor_variant, intron_variant | 1 | NM_000026.4 | ENSP00000485525.1 | ||||
ENSG00000284431 | ENST00000639722.1 | n.153+1G>T | splice_donor_variant, intron_variant | 5 | ENSP00000492828.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.89e-7 AC: 1AN: 1450776Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 721410
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jul 26, 2016 | The c.153+1G>T pathogenic variant in the ADSL gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. This splice site variant destroys the canonical splice donor site in intron 1. It is predicted to cause abnormal gene splicing, either leading to an abnormal message that is subject to nonsense-mediated mRNA decay, or to an abnormal protein product if the message is used for protein translation. The c.153+1G>T variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. We interpret c.153+1G>T as a pathogenic variant. - |
Adenylosuccinate lyase deficiency Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 20, 2022 | This variant is not present in population databases (gnomAD no frequency). This sequence change affects a donor splice site in intron 1 of the ADSL gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ADSL are known to be pathogenic (PMID: 10888601, 20177786). This variant has not been reported in the literature in individuals affected with ADSL-related conditions. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 449773). - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Apr 28, 2017 | The c.153+1G>T (NM_000026.2 c.153+1G>T) variant in ADSL has not been reported in individuals with clinical features of adenylosuccinate lyase deficiency, and wa s absent from large population studies. This variant occurs in the invariant reg ion (+/- 1,2) of the splice donor consensus sequence of exon 1 and would be pred icted to cause altered splicing. However, exon 1 is not always transcribed and/ or translated such that the impact of this variant is less certain. In summary, additional data are required to determine the clinical significance of this var iant. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at